VISTA (V-domain immunoglobulin suppressor of T cell activation) is an immune checkpoint receptor expressed primarily on the surface of hematopoietic cells. Specifically, VISTA is expressed on naïve CD4+ T cells and regulatory T cells. And it is up regulated in vivo on activated monocytes and dendritic cells. VISTA inhibits CD4+ and CD8+ T cell proliferation, and their production of the proinflammatory cytokines IL 2 and IFN gamma. VISTA protein is also observed on the surface of cancer cells and attenuates the anti tumor immune response enabling tumor progression. In the autoimmune disease model EAE, VISTA limits disease progression by downregulating the overactive immune system. VISTA, also known as B7 H5, PD-1H, Platelet receptor Gi24, Dies1, and SISP1, is a 55 65 kDa transmembrane glycoprotein with homology to B7 like immune co stimulatory molecules. VISTA supports the differentiation of embryonic stem cells (ESC) and enhances BMP 4 induced signaling in ESC but is also down regulated following BMP 4 exposure . It binds to BMP 4 directly and also associates with the type I BMP receptor Activin RIB/ALK 4. The identification of a binding partner for VISTA proved elusive for many years until two 2019 publications identified two distinct ligands for VISTA, VSIG-3 and PSGL-1. Both ligands are expressed on T cells and blocking antibodies to VISTA have been shown to reverse immune suppression making VISTA a potential therapeutic target for cancer.

高纯度、高活性、低内毒素、高批间一致性

产品数据

-25 ~ -15℃保存，收到货之后有效期1年。
复溶后， 无菌条件下，-85 ~ -65℃保存，3个月有效期。